Introduction {#S1}
============

Twin and family studies suggest that obsessive-compulsive disorder (OCD) has a genetic basis, but a major causative gene(s) for the disorder has not yet been identified. Segregation analyses suggest that OCD is transmitted as either an autosomal dominant or codominant trait, particularly in those with disease onset before adulthood. ([@R3]--[@R5]) The first linkage study of OCD found evidence for suggestive linkage (LOD=2.25) to chromosome *9p24* in 56 individuals from 7 pedigrees at marker D9S288. ([@R6]) Additional evidence of linkage to this locus (HLOD=2.26) was observed in a sample of 50 pedigrees with markers D9S1813 and D9S1792 which are located within 0.5 cM (\<350 kb) of D9S288 ([@R7]) and two of the markers tested gave modest evidence of association (p= 0.046 and 0.02). The gene encoding the neuronal glutamate transporter *SLC1A1* is located in the *9p24* linkage region and has been found to have genetic association with OCD by several groups ([@R8]--[@R10], [@R69]). It is likely that there are additional genomic loci for OCD as a substantially larger genome-wide linkage scan observed suggestive linkage to chromosomes *3q, 7p, 15q, 6q,* and *1q*, although it did not strongly support linkage to *9p24*. ([@R11])

The gene for another transporter of neurochemical importance, *SLC6A4* (*serotonin transporter*, *5-HTT,* or *SERT*), located on chromosome *17q11.1-q12*, has also been studied extensively for genetic association to OCD. *SLC6A4* is the molecular target of the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram. SSRIs collectively represent the most clinically effective and widely studied pharmacological treatment for OCD; they are effective in reducing both the thought (obsessions) and behavioral (compulsions) components of OCD. ([@R12]) Imaging studies have suggested that individuals with OCD have decreased serotonin transporter availability in the midbrain/brainstem. ([@R13]--[@R15])

A large amount of genetic variation has been observed in *SLC6A4* including both rare and common SNPs ([@R16]), repeat polymorphisms in introns 2 and 7, and an extensively studied functional 44-base pair indel polymorphism in the promoter region (5-HTTLPR). Both the 5-HTTLPR and the intron 2 polymorphism have been shown to affect transcription of *SLC6A4*. ([@R17]--[@R18]) While the initial reports suggested association between the LPR and OCD ([@R19]--[@R20]), most subsequent studies have been negative. ([@R21]--[@R28]) More recently, Dickel and colleagues ([@R10]) failed to detect association with OCD when examining select polymorphisms in *SLC6A4*, including the LPR. They carried out a meta-analysis constituted of five prior reports consisting of both positively and negatively associated findings that did not support a combined-sex association for either the long (L) or short (S) allele, after correction. However, they found nominally significant excess transmission of the L allele in females but not males. Lin ([@R29]) expanded the scope of investigation by meta-analysis of association findings of the LPR and OCD by pooling results from 13 independent case-control association studies with 3445 subjects (1 242 OCD patients and 2 203 controls). All 13 studies used an OR (odds ratio) estimator of risk, and random effects modeling showed OCD associated with the SS genotype and inversely associated with the LS genotype (OR=1.21 and p=0.04 vs. OR=0.79 and p=0.03, respectively). No association was detected for the LL genotype nor solely the allelic L variant.

Most recently, further meta-analysis ([@R18]) analyzed a larger set of case-control and, additionally, family based association findings. No evidence of association with variation at the LPR locus and OCD was detected in the overall meta-analysis. However, stratified meta-analysis demonstrated significant association between the L allele and OCD in family-based association testing and in studies involving children (child-onset OCD) and Caucasians. However, the authors note that no adjustments were made to the significance threshold for multiple comparisons.

The simple model of the 5HTTLPR having a long allele (L) with higher expression and a lower-expressing short (S) allele has been refined with the discovery of additional nearby variation that influences transcription. Hu and colleagues ([@R1]) showed that a G allele at rs25531 located within the LPR on an L background (designated L~G~) creates a functional *AP2* transcription-factor binding site and has a serotonin reuptake activity of an S allele. This group then found that the gain of function L~A~/L~A~ genotype was twice as common in OCD cases (n=169) as in ethnically matched controls (n=263) and the L~A~ allele showed a 2-fold over-transmission in OCD-affected trios (n=175), leading to a 1.8-fold increased risk of OCD.

Rare genetic variation in *SLC6A4* also has been implicated in the pathogenesis of OCD. A SNP in exon 8 alters amino acid 425 from isoleucine to valine (I425V), resulting in a protein with an increase in V~max~ and decrease in KM. ([@R30]) This variation was observed to segregate with OCD in two OCD-dense families and all six of the individuals with 425V whom could be psychiatrically assessed had either OCD or OCPD. ([@R2]) Additional studies have found a prevalence of 425V of 1.5% in OCD cases (n=530) as compared to 0.2% in controls (n=1 300), with p= 0.004 and an OR= 6.54. ([@R31])

Given the large (n=1 241), multi-center US family sample we have collected, we investigated comprehensively whether genetic association of OCD to multiple *SLC6A4* polymorphisms and haplotypes are observed using family-based statistical approaches.

Materials and Methods {#S2}
=====================

Human Subjects. {#S3}
---------------

The OCD Collaborative Genetics Study (OCGS) is an ongoing, NIMH-funded collaboration among investigators at seven sites in the US (Brown University, Columbia University, University of Southern California, Johns Hopkins University, Massachusetts General Hospital, University of California at Los Angeles, and the National Institute of Mental Health). The methods of the study are described in detail elsewhere ([@R32]) and summarized below.

The OCGS targeted families containing at least one sibling pair both affected with OCD and extended these pedigrees when possible through affected first- and second-degree relatives. Family history interviews were conducted to determine that there were at least two OCD-affected siblings in the family who were willing to participate and to identify additional affected relatives. All first- and second-degree relatives were considered for inclusion, and families were extended through the first-degree relatives of all affected cases.

To be considered affected, a participant had to meet DSM-IV OCD diagnostic criteria at any time in his or her life. Probands were included if, in addition to meeting DSM-IV criteria, their first onset of obsessions and/or compulsions occurred before 18 years of age. Probands with schizophrenia, severe mental retardation, Tourette's disorder (TD), or secondary OCD (OCD occurring exclusively in the context of depression) were excluded. Participants had to be at least 7 years old to participate in the study.

SNP genotyping. {#S4}
---------------

13 SNPs were genotyped using SNPlex chemistry according to manufacturer's instructions (protocol P/N 4360858 Revision B) and genotype calls were made using Applied Biosytems (ABI, Foster City, CA) GeneMapper™ v4.0 Software. A SNP set was assembled using data from phase I of the HapMap Project ([hapmap.org](http://hapmap.org)) and a "tag" set of SNPs was generated using the Tagger server ([broad.mit.edu/mpg/tagger/index.php](http://broad.mit.edu/mpg/tagger/index.php)), using parameters of pairwise tagging, r^2^ of 0.99, and a MAF threshold of 1%. Additional non-synonymous SNPs were selected with preference given to those with reported allele frequencies. Overall genotyping completion rate for the 13 SNPlex-assayed SNPs was 98.5% (96.7--99.0%). The discordance rate for 48 randomly-plated blind duplicates was 3 genotypes in 624 total genotypes (0.5%).

381-Base pair deletion genomic DNA amplification. {#S5}
-------------------------------------------------

Amplification was performed in a final volume of 5 μL containing 20 ng genomic DNA template, 200 uM dNTPs, 1.5 M betaine (Sigma-Aldrich, St. Louis, MO), 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 2.5 mM MgCl~2~, 200 nM primers (F-CTCCAGCATTCTCCTTGCAC and R-TGAGCCCAGGAATTCAAGAC (Invitrogen, Carlsbad, CA)), and 0.25 units Platinum Taq DNA polymerase (Invitrogen), then cycled at 95°C for 1 min, followed by 10 cycles at 95°C for 20 sec, 61°--56°C for 20 sec (decreased by 0.5°C intervals per cycle), and 72°C for 1 min, followed by 35 cycles at 95°C for 20 sec, 56°C for 20 sec, and 72°C for 1 min, with a final 30 min at 72°C on a DNA Engine Dyad PTC-220 thermal cycler (MJ Research, Waltham, MA). Amplified samples were run on 2% agarose in 1XTBE with EtBr (Cambrex Bio Science, Rockland, ME) and examined under UV fluorescence.

Microsatellite and LPR genotyping. {#S6}
----------------------------------

A PCR "triplex" for *SLC6A4* LPR, intron 2, and intron 7 was performed in 2.5 μL containing 25 ng genomic DNA template, 400 μM dNTPs, 1.5 mM 10X PCR Buffer IV (Abgene, Surrey, UK), 3.0 mM MgCl~2~, 200 nM primers for the LPR (F-FAM-ATGCCAGCACCTAACCCCTAATGT; R-GGACCGCAAGGTGGGCGGGA), 200 nM primers for intron 2 (F-FAM-GTCAGTATCACAGGCTGCGAG and R-TGTTCCTAGTCTTACGCCAGTG), 100 nM primers for intron 7 (F-HEX-ACCGCACCCCGTCTCTCTCTTT and R-ACACCTGTAAGCACAGCCACTTG) (Invitrogen), and 1.0 unit Platinum Taq DNA polymerase (Invitrogen), then cycled according to the following protocol: at 96°C for 5 m followed by 35 cycles of 96°C for 45 s, 68°C for 30 s and 72°C for 1 m, followed by a final extension at 72°C for 10 m on a DNA Engine Dyad PTC-220 thermal cycler. Samples were then subjected to capillary electrophoresis on an ABI 3100 fragment analyzer (ABI) and the following size ranges were observed: 5-HTTLPR, 375 or 419 bp; Int2 VNTR, 260--310 bp; and Int7 GAAA, 263--288 bp. Microsatellite genotyping calls were made using Gene Marker v1.5 software (SoftGenetics, LLC, State College, PA). Forty-eight randomly distributed blind duplicates revealed no discordances. This assay achieved the following genotype completion rates: LPR, 99.6%; Int2, 98.2%; and Int7, 99.6%.

LPR-rs25531 (A/G) SNP variant. {#S7}
------------------------------

Phase-certain haplotyping of the LPR variants L~A~, L~G~, S~A~ and the rare S~G~ allele was performed by a 2-step protocol: I. determination of the LPR L or S allele, as above; and, II. digestion of this amplicon with *MspI* restriction endonuclease. The assay was designed to include an invariant *MspI* digest site 94 bp from the end of the LPR amplicon to provide an internal control for digestion/partial digestion ([OS figure 2](#SD3){ref-type="supplementary-material"}). After separation of the digestion products by capillary electrophoresis and analysis using Gene Marker v1.5, the following restriction fragment allele sizes were obtained: S~A~ (281 bp), L~A~ (325 bp), S~G~ and L~G~ (151 bp). When these data are combined with the results from the undigested fragment data, unambiguous haplotypes can be deduced (see legend to [OS figure 2](#SD3){ref-type="supplementary-material"}). All of the rare S~G~ alleles were confirmed by capillary DNA sequencing. The 48 randomly distributed blind duplicates were 100% concordant. Completion rate for the LPR-rs25531 genotyping (step II) was 96.5%.

Statistics. {#S8}
-----------

### Family-based association analysis. {#S9}

We used FBAT and PDT (<http://www.chg.duke.edu/software/pdt.html>) ([@R33]--[@R35]) to run two-point SNP analyses under additive, dominant and genotypic models and for haplotype-based association analysis.

### Corrections for multiple testing. {#S10}

Two-point p-values from FBAT were corrected for multiple-marker testing in the presence of linkage disequilibrium (LD), and also multiple-model assessments, but not gender. The PACT ([p]{.ul}-values [a]{.ul}djusted for [c]{.ul}orrelated [t]{.ul}ests) approach adjusts for multiple comparisons by calculating the null distribution of the test statistics through numerical integration of their asymptotic joint distribution. This approach has been shown to be reliable and highly efficient for adjustment of multiple-comparisons. ([@R36])

### Haplotype analysis and haplotype phasing. {#S11}

We used Haploview 4.1 to assess LD structure at the *SLC6A4* locus using the OCGS genotype data (17 markers). We adopted 2 LD blocks defined by the solid spine approach (extension with D'\> 0.95) that encompassed our set of polymorphic markers for all haplotype analysis in FBAT ([OS Figure 3](#SD4){ref-type="supplementary-material"}). The HapMap phase III dataset supported this LD block structure ([OS Figure 4](#SD6){ref-type="supplementary-material"}). Haplotype analysis was performed on only the Caucasian portion of the sample by removal of 47 individuals who reported non-Caucasian ethnicity, which included 5 entire pedigrees (see [Table 4](#T4){ref-type="table"}, pedigree ethnicity summary).

In our haplotype analysis we assigned the most likely estimated haplotype to each individual. Given that the haplotypes were estimated within haplotype blocks with tight LD structure for SNPs within a block, haplotype diversity was low with estimated haplotype posterior probabilities within each block greater than 92%. Thus, the method of assigning the most likely haplotype yields similar results to an approach using the expectation or haplotype dosage ([@R37]--[@R39]) The permutation method implemented in FBAT was used to compute haplotype whole-marker (minimal) p-values ([biostat.harvard.edu/\~fbat](http://www.biostat.harvard.edu/~fbat)).

### Genotype Relative Risk (GRR). {#S12}

Conditional logistic analysis was carried out using the STATA package (<http://www-gene.cimr.cam.ac.uk/clayton/software/stata>).

### Power calculations. {#S13}

In separate calculations assessed in PBAT (<http://www.goldenhelix.com/SNP_Variation/PBAT/pbat_methodology.html>), the power to detect association assuming an additive model of inheritance with a disease allele frequency of 0.05 and a population prevalence of 0.03 using the 278 families (459 nuclear families) already collected is roughly 0.60 (if the D' between the disease locus and candidate SNP is 1.0).

### Sex-stratified Analyses. {#S14}

We stratified the dataset by the gender status of male or female OCD-affecteds in each family. We coded the affection status of either all female OCD-affecteds as "unknown", or all male affecteds as "unknown," and analyzed with FBAT. P-values for sex-stratified analyses were not corrected for the three hypotheses tested (all, male-only, female-only).

Results {#S15}
=======

We genotyped 278 pedigrees containing 459 nuclear families and 1 241 persons (\>96% Caucasian pedigrees; see [Table 4](#T4){ref-type="table"}) with 14 SNPs, the LPR indel and two VNTR polymorphisms in introns 2 and 7 within *SLC6A4* to determine if they are in linkage disequilibrium (LD) with OCD ([Table 1](#T1){ref-type="table"}, [OS Figure 1](#SD2){ref-type="supplementary-material"}). Three SNPs, rs6353 (MAF= 0), I425V and rs140699 (MAFs= 0.003) with low minor allele frequencies (MAF) did not have a sufficient number of families to calculate 2-point results with FBAT and were also excluded from the haplotype analysis. In addition, we also failed to detect a 381-bp deletion variant immediately 3' of the LPR ([@R40]) in 354 randomly selected samples from 102 families. All other SNP data were confirmed to be in Hardy-Weinberg equilibrium (HWE) and were used to determine the haplotype structure in the region, which was in agreement with the haplotype structure of *SLC6A4* observed with HapMap Project phase III data ([OS Figures 3](#SD4){ref-type="supplementary-material"} & [4](#SD6){ref-type="supplementary-material"}).

We performed two-point analyses using FBAT under additive, dominant, recessive and genotypic models and the results for the additive model are presented in [Table 2](#T2){ref-type="table"}, parts A and C. All allele-model combinations for the whole sample that yielded nominal p-values \<0.05 are presented in [Table 3](#T3){ref-type="table"}. Specifically, under an additive model we observed nominal evidence of positive association with allele 5 of the microsatellite repeat in intron 7 (p= 0.0330; 14 informative families). Under a genotypic model, the intron 2 genotype containing alleles 9/10 showed positive association (p-value= 0.0089; 13 families), and the intron 7 genotype containing alleles 3/7 was inversely associated with OCD (i.e., reduced risk) (p= 0.0187; 105 families). Given that a number of correlated tests were performed and that significant LD existed within the set of markers (see [OS Figure 3](#SD4){ref-type="supplementary-material"}), we employed the method of Conneely and Boehnke ([@R36]) to correct jointly for multiple marker comparisons, in the setting of LD. On the full sample, none of the resulting 2-point analysis adjusted P-values (P~Adj~) were \<0.05 ([Table 3](#T3){ref-type="table"}). The results did not change appreciably when analyzed with the PDT.

The most notable negative results were at the LPR locus. We found no evidence of association to either the LPR polymorphism, or to the molecular haplotype of LPR-rs25531 with any of the genetic models (additive model data shown in [Table 2](#T2){ref-type="table"}, [OS Table 1](#SD5){ref-type="supplementary-material"}). We did observe 10 individuals with the S~G~ variant, all of which were confirmed by DNA sequencing. Two of these individuals had a LPR variant similar to that as reported previously (see variant 14B in ([@R41])) (data not shown). We investigated whether these results were influenced by either genotypic (e.g., LPR allele frequencies) or phenotypic heterogeneity (e.g., % females, ethnicity, mean age of onset of symptoms) across the different clinical sites. No evidence of either genotypic or phenotypic heterogeneity was observed ([Table 4](#T4){ref-type="table"}). Furthermore, we did not observe association of the LPR-rs25531 haplotype when each site was analyzed individually.

Three individuals with the rare 425V variant were detected and we examined their pedigrees in greater detail. In all three, the individual with 425V was the biological parent of an OCD affected sib-pair. Two of the carriers were fathers: one with OCD (1808--3), one with OCPD (2113--69); the third was an unaffected mother (2947--68). However, none of these individuals passed the 425V variant to their OCD-affected sibpair offspring (confirmed by DNA sequencing). This non-segregation of 425V to the 6 OCD-affected offspring was unexpected; such segregation by chance alone should only occur 1/64th of the time. Two of the 425V carriers were diagnosed with depressive disorders (1808--3 probable MDD and 2947--68 recurrent MDD/dysthymia), two had skin picking (1808--3 (probable) and 2947--68 (definite)); and two had probable alcohol dependence (1808--3 and 2113--69) (see [OS Table 2](#SD8){ref-type="supplementary-material"}).

We also analyzed the data stratified by sex by FBAT (similar PDT results), under the hypothesis that genetic loci for OCD may be sex-specific ([Tables 2](#T2){ref-type="table"} & [3](#T3){ref-type="table"}). One SNP, rs2020930 located 5' to the LPR had a nominal p-value of \<0.05 in males, but this did not withstand correction for multiple testing (P~Adj~= 0.3379). The most statistically significant 2-point findings were obtained using a genotypic model and showed association in females with intron 2 alleles 9/10 (p-value\< 0.0002; 10 informative families). With P~Adj~= 0.0054, this finding withstood the joint correction for multiple marker comparison and LD. We then further adjusted the statistical significance for the testing of multiple genetic models, and the result remained significant (P~MAdj~= 0.0069) ([Table 3](#T3){ref-type="table"}). Even using a conservative Bonferroni correction for the testing of 3 sex-based models (all, male-only, female-only) this result is still significant after correction for all tests done (p\< 0.017).

Lastly, we carried out a haplotype analysis with FBAT for the two observed haplotype blocks using the entire and sex-stratified Caucasian sample. The 5' block (rs2020930:rs4392119:LPR-rs25531:rs25533:rs2020933) contained the LPR and the first exon while the 3' block (rs6355:Int2:rs140700:Int7:rs4583306:rs7224199) includes the rest of the gene ([Table 2](#T2){ref-type="table"}, [OS Figures 3](#SD4){ref-type="supplementary-material"} & [4](#SD6){ref-type="supplementary-material"}). Neither block achieved whole-marker significance using a permutation test. In the 5' block, four individual haplotypes had p\<0.05 of the 18 observed haplotypes. Interestingly, both individual haplotypes containing a high expressing L~A~ allele conferred risk (ACL~A~TA and GTL~A~TT, albeit in different sexes), while the two individual haplotypes containing low expressing alleles (GTS~A~TT and GCL~G~TT, principally in males) were protective. We note that the individual haplotypes GTL~A~TT and GTS~A~TT are identical except at LPR-rs25531, yet have opposite effects on OCD risk. In the 3' block of 6 markers (including 2 microsatellites) and 25 observed individual haplotypes, three haplotypes with p\< 0.05 were observed. Two of these contain the 267 bp allele at intron 2, which is part of the 250/267 genotype that was significant after correction. The set of 10 female families (250/267 genotype, [Table 3](#T3){ref-type="table"}) overlapped with the set of 8 female families (267 bp allele- containing haplotype, [Table 4](#T4){ref-type="table"}) in only a single female. We note that individual haplotype p-values are uncorrected for multiple testing.

Discussion {#S16}
==========

The serotonin transporter, *SLC6A4*, is the molecular target of the selective serotonin reuptake inhibitors (SSRIs), which are the current medications of choice for the treatment of OCD. There have been multiple genetic association studies of OCD and *SLC6A4* and while some of these have been positive, overall the results have been equivocal. In an effort to determine whether variation in *SLC6A4* alters the probability of an individual developing OCD, we genotyped 1,241 DNA samples from the OCGS OCD-affected sib pair study (278 pedigrees, 459 nuclear families, 1 598 total persons) with 17 marker loci.

After correction for multiple testing with several models and marker loci, none of the two-point results using the entire sample remained statistically significant. Given the suggestion of gender differences that have been observed in genetic association studies of OCD and *HTR2A, COMT* and *MAOA* ([@R42]--[@R44]) and also in segregation studies ([@R3]), we also analyzed our data stratified by sex, under the hypothesis that genetic loci for OCD may be sex-specific. In these analyses, genotype 9/10 of the Int2 VNTR was associated with OCD in females both before (p\< 0.0002), and after correction for LD structure and multiple marker comparisons (p~Adj~= 0.0054). This result remained significant after we further corrected for the testing of additive, dominant, recessive and genotypic genetic models (P~MAdj~= 0.0069). There have been suggestions of sex-specific OCD findings for *SLC6A4*, for the LPR, in a Dutch sample ([@R45]) and a recent meta-analysis ([@R10]); the latter did not withstand multiple-marker nor multiple-analysis corrections, while the former may have. While we approached sex differences in the conferring of OCD risk as separate hypotheses, we note that even with additional correction, findings remain significant with p\< 0.0167.

In the OCGS sample, there appears to be little difference in the OCD symptomatology between males and females. There are no sex differences in YBOCS severity scores, numbers of different categories of obsessions or compulsions, or in the proportions treated for their OCD symptoms. There are sex differences in prevalence of several Axis I disorders, females showing more recurrent major depression (MD), hypomania, dysthymia, hypochondriasis, skin picking, panic disorder, agoraphobia, social phobia (SP), generalized anxiety disorder (GAD), anorexia and bulimia and less TD, alcohol dependence and Asperger's Syndrome. ([@R32]) Serotonin has been hypothesized to play a role in many of these disorders. Given that the majority of OCD-affected individuals in the OCGS sample are female (66%), it is possible that the observation of the association to alleles 9/10 of the Int2 VNTR in the OCGS females may be due to presence of co-morbid Axis I disorders, rather than OCD.

There have been previous observations of association of alleles at the Int2 marker with a number of neuropsychiatric disorders. Allele 9 has been associated with both unipolar depression ([@R46]--[@R47]) and depression in the context of bipolar disorder (BPD). ([@R47]) The Int2 allele 12 has been associated with BPD ([@R48]), schizophrenia (meta-analysis) ([@R49]), autism ([@R50]), and anxiety disorders with and without OCD, in Japanese subjects, but not Caucasians. ([@R51]) Additionally, less favorable SSRI treatment response was observed in Asians with major depression and the Int2 10/12 genotype in a meta-analysis. ([@R52]) More recently, study of OCD in a Spanish Caucasian sample found an excess of 12/12 and 12/10 genotypes in cases. ([@R53])

The functional mechanism driving the associations of these Int2 alleles *in vivo* may be complex and may involve combined effects with the linked polymorphic region (LPR) polymorphism. ([@R54]) VNTR copy number variation has been shown to have effects on transcription ([@R55]), as have VNTR sequence variants on differential reporter gene expression. ([@R56]) Recent investigation of the Int2 VNTR as a target for mediating a transcriptional response to LiCl via the transcription factors *CTCF* and *YB-1*, found that *in vivo* transcriptional variation was correlated with differential binding of both these transcription factors to the three distinct VNTR variants after exposure to LiCl, suggesting differential allelic gene expression. ([@R17])

Although there is evidence that the Int2 VNTR can influence the expression of *SLC6A4*, it is the LPR indel that has been most extensively studied. Early studies of the LPR by Lesch and colleagues observed that the transcriptional activity of the L allele was 2- to 3 fold higher than that of the S allele in lymphoblastoid cell cultures. ([@R57]) The L allele was associated with higher platelet serotonin uptake. ([@R70]--[@R71]) Consistent with many prior reports, we failed to detect association of the LPR with OCD in the OCGS sample, either in the combined-sex data or when analyzing by sex.

It appears that additional variation within the LPR affects the strength of the *SLC6A4* promoter. Hu and colleagues showed that the A to G base change at rs25531 within the LPR forms a haplotype (L~G~) that has comparable low activity to the S allele. ([@R1]) They also found that the L~A~ allele was associated with OCD in both case-control and trio samples and conferred a 1.8-fold increased risk (OR) of developing the disorder. One other published report of the haplotype found equivocal replication with L~A~/L~A~, or L~A~ alone, in a case-control study of 347 OCD-affecteds vs. 749 population-matched controls, and results did not withstand correction for multiple testing. ([@R58]) We generated phase-certain haplotypes of the LPR-rs25531, but failed to observe any evidence that the L~A~/L~A~ genotype conferred risk for OCD. In addition, we did not observe an association to either L~A~ or L~G~ under additive, dominant models, recessive or genotypic models, either in the total data set or when stratified by sex. In our sample the GRR for the L~A~/L~A~ genotype vs. all others was 1.11 (95% CI: 0.77--1.60, p= 0.58). While positive, this risk estimate is markedly less than that reported by Hu et al (see also [OS table 1](#SD5){ref-type="supplementary-material"}).

Phenotypic and/or genotypic heterogeneity may have contributed to lack of replication in this multi-site association study. Factors such as ethnicity, method of ascertainment, site of patient recruitment, mean age at time of patient recruitment, and mean age at onset of OCD symptoms all may play a contributory role. We did not observe significant differences when analyzing these parameters by site of patient recruitment. We then assessed for genetic heterogeneity in our sample by examining LPR L and S allele-, and LPR-rs25531 haplotype frequencies in the OCGS sample by site. We did not detect significant differences.

Alternatively, it is possible that our results differ from those of Hu and colleagues ([@R1]) due to additional unmeasured genetic variation in the *SLC6A4* gene that has a functional effect on the promoter of the gene. Two SNPs in the first intron of *SLC6A4*, rs16965628 and rs2020933 were shown correlated with allelic expression imbalances ([@R59]) and rs25532 has been suggested to affect expression. ([@R58]) The latter report described a functional C to T single nucleotide polymorphism (rs25532) located near the LPR; its minor allele significantly decreased luciferase reporter gene expression levels. Haplotype-based testing of rs25532 and all other known non-coding functional *SLC6A4* variants revealed significant overrepresentation in probands who had the higher-expressing allele at each locus, supporting the notion of increased serotonin transporter functioning being pathogenetically involved in OCD. Conditional haplotype analyses revealed that this association was driven by the LPR, rs25532 and rs16965628 in concert. Finally, our results may differ from those of Hu and colleagues due to the characteristics of the respective samples. The OCGS sample is composed entirely of familial OCD cases ([@R33]), whereas case-control and trio samples will contain a higher proportion of sporadic cases that may have a different genetic basis.

We also investigated several rare variants within *SLC6A4* to determine if they were associated with OCD in our sample. We found no individuals with either rs6353 (T439T) or the 381-bp deletion variant immediately 3' of the LPR that has been previously shown to contain several canonical transcription factor binding sites. Rs6353 is thought to be functional ([@R56],[@R16]) and has been associated with both autism and depression. ([@R61],[@R62]) We also investigated the rare SNP that causes a non-synonymous change from isoleucine to valine at position 425 of *SLC6A4* that has been suggested to contribute to an uncommon familial form of OCD in two unrelated pedigrees with OCD and other serotonin-related comorbidities. ([@R2]) We observed three individuals from three pedigrees with 425V, all of whom are parents of OCD affected sib-pairs. Collectively, these 3 individuals had 6 OCD affected offspring, none of whom received the 425V allele from these parents, a result that should occur in only 1/64^th^ of such segregations. These genetic data are not supportive of the hypothesis that 425V is solely responsible for the "OCD plus syndrome". ([@R2],[@R63]) We also tested the "double-hit" hypothesis proposed by Ozaki and colleagues ([@R2]), in which homozygosity of the L-allele plus the 425V variant, which increase both transcription and functional activity, and hence increases the risk for OCD. Consistent with this hypothesis, the single 425V carrier who was affected with OCD is homozygous for the LPR L allele. Haplotype analysis of LPR-rs25531 revealed that this individual is L~G~/L~A~, and hence a functional heterozygote. Haplotype analysis of the three pedigrees segregating the 425V variant found that this rare variant was found on an LPR L~A~ background (the other two 425V carriers were S/L~A~), suggesting one mutation event, possibly as a shared ancestral event in these pedigrees. The 425V allele has been observed in controls ([@R60],[@R63]) and in another study in families with pervasive developmental disorders, eating disorders and OCD, but other large studies on various types of patients and controls have failed to detect it ([@R64],[@R65]). Non-transmittal of the 425V allele to 6 definite OCD cases proves that those OCD cases in high-density OCD families have some other cause of their OCD.

Ozaki and colleagues have suggested the 425V variant as a possible mediator of SSRI treatment response or as a mediator/exacerbator of neuropsychiatric comorbidity. ([@R2]) They hypothesized an "atypical OCD plus", a syndrome incorporating OCD plus AS/autism/social phobia and eating disorders. We failed to find support for either of these hypotheses, as we observed no instances of 425V in the 32 self-reported SSRI treatment non-responders, and while each of the three 425V carriers do have a complex neuropsychiatric phenotype, it differs from "atypical OCD plus". We suggest that 425V might predispose to a spectrum of complex serotonergic phenotypes that is wider than that observed by Ozaki et al, and that OCD may not be a necessary component of this spectrum.

Family-based haplotype reconstruction has demonstrated higher reliability when compared to haplotype reconstruction from unrelated individuals. ([@R66]) When analyzing haplotypes, we excluded the small number of non-Caucasian pedigrees that may have contributed to heterogeneity. Several less common individual haplotypes do show the L~A~ allele associated with OCD risk, and the S~G~ and S~A~ alleles comparably associated with inverse risk. In contrast, 2-pt analysis at the LPR showed no association with OCD. Investigation of the COMT gene recently showed that while single variants might fail to show association (e.g., COMT V158M), functional haplotypes containing these alleles can show strong association (e.g., TMJ disorder and pain sensitivity). ([@R67]) The selection of haplotype blocking algorithm in the context of degree of LD at the given locus is known to affect association findings and type 1-error rates. ([@R68]) We noted that several of the blocking algorithms (e.g., Gabriel et al., Patil et al.) gave marginally significant findings after correction for the number of LD blocks tested in the 3' haplotype block, notably when a significant portion of the marker set was excluded (e.g., Gabriel algorithm) or when haplotype "windows" approached small numbers of markers (e.g., Patil algorithm). Hence, the full significance of these individual haplotypes has yet to be determined; some may confer appreciable risk in a genotypic subset of this sample.

In conclusion, we found evidence of genetic association at the *SLC6A4* locus with OCD. Noteworthy was the lack of association at the LPR, the LPR-rs25531 haplotype, and the rare 425V variant. Current hypotheses about the risk of specific variants need revision to accommodate these new findings, including a possible gender effect.
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###### 

FBAT analysis of 17 markers spanning the *SLC6A4* locus

  Marker                                             Notes (bp)                                                 NCBI Build 126 bp   GT comp. %^[3](#TFN3){ref-type="table-fn"}^
  -------------------------------------------------- ---------------------------------------------------------- ------------------- ---------------------------------------------
  **rs1487971**                                      5′ near *BLMH*                                             25,596,879          98.6
  **rs2020930**                                      5′                                                         25,590,167          98.7
  **rs4392119**                                      5′                                                         25,589,489          96.7
  **LPR**                                            (42--44)~usu.\ 7--9~                                       1.2 kb 5'           99.6
  **LPR-rs25531**^[1](#TFN1){ref-type="table-fn"}^   See [OS fig 2](#SD3){ref-type="supplementary-material"}.   25,588,472          96.5
  **rs25533**                                        5′                                                         25,587,018          97.5
  **rs2020933**                                      Intron 1                                                   25,585,881          98.7
  **rs2066713**                                      Intron 1                                                   25,575,791          99.0
  **rs6355**                                         G56A; exon 1                                               25,572,936          98.6
  **Intron 2**                                       (16--17)~9,\ 10\ or\ 12~                                   25,572,759          99.2
  **rs140699**^[2](#TFN2){ref-type="table-fn"}^      Intron 4                                                   25,569,251          98.1
  **rs140700**                                       Intron 5                                                   25,567,515          98.8
  **Intron 7**                                       (GAAA)~1--7~                                               25,566,563          99.6
  **rs4583306**                                      Intron 8                                                   25,562,841          98.5
  **I425V**^[2](#TFN2){ref-type="table-fn"}^         Exon 8                                                     25,562,500          98.9
  **rs6353**^[2](#TFN2){ref-type="table-fn"}^        T439T; exon 8                                              25,562,456          98.7
  **rs7224199**                                      3′                                                         25,547,852          99.0

LPR-rs25531 indicates molecular haplotype of the LPR: L vs. S allele and rs25531 A vs. G, yielding 4 haplotypes.

Nonpolymorphic SNPs excluded from all haplotype analysis.

Completion % of respective genotyping assay.

###### 

FBAT analysis of *SLC6A4* locus: 2-pt & haplotype analysis (additive model)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A. 2-pt analysis by SNP                            B. Haplotypes (Caucasians)^[1](#TFN4){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                                                            
  -------------------------------------------------- ------------------------------------------------------------- ------- ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ -------- -------------------------
  **rs1487971**                                      G**/A**                                                       0.379   157                                  1.009                                100                                  0.582                                133                                  0.780                                0.3132                               0.5607                               0.4357   

  **rs2020930**                                      G**/A**                                                       0.049   38                                   0.616                                20                                   1.877                                31                                   −0.609                               0.538                                0.0606                               0.5428   5' Block:\
                                                                                                                                                                                                                                                                                                                                                                                                                                            0.1322 (0.1716, 0.0944)

  **rs4392119**                                      C/**T**                                                       0.028   23                                   −0.897                               9                                    [\*\*](#TFN7){ref-type="table-fn"}   25                                   0.278                                0.3696                               [\*\*](#TFN7){ref-type="table-fn"}   0.7809   

  **LPR-rs25531**^[5](#TFN9){ref-type="table-fn"}^   See C. below                                                                                                                                                                                                                                                                                                                                                                           

  **rs25533**                                        T**/C**                                                       0.053   38                                   1                                    20                                   0                                    32                                   1.206                                0.3173                               1                                    0.2278   

  **rs2020933**                                      T**/A**                                                       0.079   54                                   −0.017                               28                                   1.635                                46                                   −1.198                               0.9863                               0.1020                               0.2308   

  **rs2066713**                                      C/**T**                                                       0.393   149                                  0.822                                99                                   0.468                                129                                  0.619                                0.4111                               0.6399                               0.5359   

  **rs6355**                                         G**/C**                                                       0.016   18                                   0.478                                6                                    [\*\*](#TFN7){ref-type="table-fn"}   17                                   −0.084                               0.633                                [\*\*](#TFN7){ref-type="table-fn"}   0.9330   3' Block:\
                                                                                                                                                                                                                                                                                                                                                                                                                                            0.1956 (0.1634,\
                                                                                                                                                                                                                                                                                                                                                                                                                                            0.1353)

  **Intron 2**                                       See C. below                                                                                                                                                                                                                                                                                                                                                                           

  **rs140700**                                       G**/A**                                                       0.078   66                                   −0.595                               36                                   −0.295                               57                                   −0.491                               0.5517                               0.7681                               0.6234   

  **Intron 7**                                       See C. below                                                                                                                                                                                                                                                                                                                                                                           

  **rs4583306**                                      A/**G**                                                       0.426   154                                  0.018                                100                                  0.069                                131                                  −0.033                               0.9855                               0.9450                               0.9734   

  **rs7224199**                                      G/**T**                                                       0.452   154                                  −0.144                               99                                   0.716                                132                                  −0.762                               0.8857                               0.4743                               0.4462   

  **C. 2-pt analysis for multi-allelic markers**                                                                                                                                                                                                                                                                                                                                                                                            

  **LPR**                                            L/**S**                                                       0.425   169                                  0.732                                114                                  0.862                                150                                  0.181                                0.4642                               0.3889                               0.8567   

  **LPR-rs25531**                                    L~A~                                                          0.504   177                                  0.493                                114                                  1.591                                148                                  −0.717                               0.6217                               0.1116                               0.4731   

  L~G~                                               0.065                                                         63      0.439                                31                                   −1.321                               53                                   1.474                                0.6606                               0.1865                               0.1404                                        

  S~A~                                               0.426                                                         165     −0.806                               109                                  −1.117                               142                                  −0.059                               0.4204                               0.2639                               0.9532                                        

  S~G~                                               0.004                                                         4       [\*\*](#TFN7){ref-type="table-fn"}   2                                    [\*\*](#TFN7){ref-type="table-fn"}   3                                    [\*\*](#TFN7){ref-type="table-fn"}                                                                                                                           

  **Intron 2**                                       9~250\ bp~                                                    0.017   17                                   0.750                                11                                   −0.277                               15                                   1.209                                0.4531                               0.7815                               0.2265   

  10~267\ bp~                                        0.376                                                         161     1.017                                104                                  0.976                                137                                  0.428                                0.3092                               0.3292                               0.6687                                        

  12~300\ bp~                                        0.607                                                         158     −1.215                               102                                  −0.912                               136                                  −0.735                               0.2244                               0.3619                               0.4623                                        

  **Intron 7**                                       1~263\ bp~                                                    0.003   7                                    [\*\*](#TFN7){ref-type="table-fn"}   4                                    [\*\*](#TFN7){ref-type="table-fn"}   3                                    [\*\*](#TFN7){ref-type="table-fn"}                                                                                      

  2~267\ bp~                                         0.016                                                         13      0.408                                8                                    [\*\*](#TFN7){ref-type="table-fn"}   15                                   −1.118                               0.6835                               [\*\*](#TFN7){ref-type="table-fn"}   0.2635                                        

  3~271\ bp~                                         0.148                                                         107     −1.64                                61                                   −1.762                               91                                   −0.673                               0.1009                               0.0781                               0.5010                                        

  4~280\ bp~                                         0                                                             0       [\*\*](#TFN7){ref-type="table-fn"}   0                                    [\*\*](#TFN7){ref-type="table-fn"}   0                                    [\*\*](#TFN7){ref-type="table-fn"}                                                                                                                           

  5~284\ bp~                                         0.018                                                         14      2.132                                8                                    [\*\*](#TFN7){ref-type="table-fn"}   12                                   2.50                                 0.0330                               [\*\*](#TFN7){ref-type="table-fn"}   0.0124                                        

  6~285\ bp~                                         0.001                                                         1       [\*\*](#TFN7){ref-type="table-fn"}   0                                    [\*\*](#TFN7){ref-type="table-fn"}   1                                    [\*\*](#TFN7){ref-type="table-fn"}                                                                                                                           

  7~288\ bp~                                         0.810                                                         118     0.817                                73                                   0.981                                101                                  0.235                                0.4137                               0.3265                               0.8141                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Haploview v4.1 analysis of LD structure at the *SLC6A4* locus: 2 haplotype blocks are indicated by grey shading (leftmost column). Haplotype most significant whole-marker permutation test p-values (minimal p) are shown for blocks I & II in Caucasian pedigrees only, uncorrected (rightmost column). We analyzed using the solid spine algorithm, with extension of the LD blocks when D'\>0.95. Non-polymorphic SNPs excluded from analysis. See [Table 5](#T5){ref-type="table"} for best individual haplotypes (p~i~).

Minor allele is shown in bold.

Throughout tabular data, fam. n indicates number of transmission-informative families;

Indicates FBAT family number threshold not achieved for analysis.

Z~all,\ m,\ and\ f~ and P~all,\ m,\ and\ f~, show the FBAT test statistic and p-value for the combined data set, males, and females, respectively.

LPR-rs25531 indicates molecular haplotyping of the LPR locus: L vs. S allele and rs25531 A vs. G, yielding the 4 haplotypes in Part C, column 2.

###### 

FBAT best models, markers and alleles with corrections for LD, multiple marker- & multiple model testing

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker          Allele(s) (bp)   Sex                  Model          Allele freq.   Fam. n       Z^[1](#TFN10){ref-type="table-fn"}^   P        P~Adj~^[2](#TFN11){ref-type="table-fn"}^   P~MAdj~^[3](#TFN12){ref-type="table-fn"}^
  --------------- ---------------- -------------------- -------------- -------------- ------------ ------------------------------------- -------- ------------------------------------------ -------------------------------------------
  **rs2020930**   G/A              M                    Genotypic      0.099          20           2.294                                 0.0219   0.3379                                     0.3772

  G/G             0.901            19                   −2.132         0.0330         0.4528       0.4978                                                                                    

  **Intron 2**    9/10\            All                  Genotypic      0.019          13           2.617                                 0.0089   0.2053                                     0.2355
                  (250/267)                                                                                                                                                                  

  **F**           **10**           **3.738**            **\<0.0002**   **0.0054**     **0.0069**                                                                                             

  **Intron 7**    3/7\             All                  Genotypic      0.241          105          −2.352                                0.0187   0.3590                                     0.4033
                  (271/288)                                                                                                                                                                  

  F               90               −1.903               0.0571         0.7155         0.7557                                                                                                 

  5\              All              Additive, Dominant   0.018          14             2.132        0.0330                                0.3719   0.5762                                     
  (284)                                                                                                                                                                                      

  F               12               2.5                  0.0124         0.1662         0.2974                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Z statistic sign indicates positive vs. negatively directed association, ie risk-conferring vs. protective allele(s).

P~Adj~ indicates p-value correction for multiple-marker testing in the context of LD within the marker set (see [Methods](#S2){ref-type="sec"}).

P~MAdj~ indicates p-value correction across multiple models, i.e., global correction (see [Methods](#S2){ref-type="sec"}).

###### 

OCGS sample heterogeneity analysis

  A. Phenotypes                                                                                                                      
  ------------------------------------- ----- ------ ----- ------- ------ ------ ----- ------ ---- ------- ---- ------ ------ ------ ------------------------------------------------
  **Subjects with DNA**                 119          73            906           45           19           64          1226          
  **Family n**                          32    16     194   12      7      17     278                                                 
  **Male n**                            45    37.8   28    38.4    358    39.5   19    42.2   5    26.3    29   45.3   484    39.5   2.61 (0.760)
  **Female n**                          74    62.2   45    61.6    548    60.5   26    57.8   14   73.7    35   54.7   742    60.5   
  **Pedigree ethnicity (by proband)**                                                                                                
  **Caucasian**                         31    96.9   16    100.0   187    96.4   11    91.7   7    100.0   15   88.2   267    96.0   
  **Black**                             1     0      0     0       0      0      0     0      0    0       0    0      1      0.4    
  **Hispanic**                          0     0      0     0       0      0      0     0      0    0       1    5.9    1      0.4    
  **Other**                             0     0      0     0       2      1.0    0     0      0    0       1    0      3      1.1    
  **Unknown**                           0     0      0     0       1      0.5    1     8.3    0    0       0    0      2      0.7    
  **OCD n**                             84    70.6   44    60.3    603    66.6   34    75.6   15   78.9    44   68.8   824    67.2   5.06 (0.408)^[1](#TFN14){ref-type="table-fn"}^
  **B. Genotypes**                                                                                                                   
  **LPR Allele frequencies**                                                                                                         
  **L**                                 122   51.3   79    54.1    1047   57.8   49    54.4   16   42.1    66   51.6   1379   56.2   6.37 (0.272)
  **S**                                 104   43.7   63    43.2    729    40.2   41    45.6   16   42.1    64   50     1017   41.5   
  **L**~**A**~                          111   46.6   76    52.1    929    51.3   38    42.2   15   39.5    64   50     1233   50.3   24.4 (0.059)
  **L**~**G**~                          11    4.6    3     2.1     118    6.5    11    12.2   1    2.6     2    1.6    146    6.0    
  **S**~**A**~                          103   43.3   63    43.2    719    39.7   41    45.6   16   42.1    64   50     1006   41.0   
  **S**~**G**~                          1     0.4    0     0       10     0.6    0     0      0    0       0    0      11     0.4    

Notes

OCD n vs. non-OCD n.

###### 

FBAT significant individual haplotypes, Caucasian pedigrees only (additive model)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Multi-marker haplotype block: markers^[1](#TFN15){ref-type="table-fn"}^                       Sex     Haplo-type freq.   \# Fam.   Z                    P~i~^[2](#TFN16){ref-type="table-fn"}^   Alleles \[bp\]^[3](#TFN17){ref-type="table-fn"}^
  --------------------------------------------------------------------------------------------- ------- ------------------ --------- -------------------- ---------------------------------------- --------------------------------------------------
  **5' Block**\                                                                                 All     0.004              6         2.111                0.0348                                   GTL~A~TT
  **rs2020930:rs4392119:LPR-rs25531**^[4](#TFN18){ref-type="table-fn"}^**:rs25533:rs2020933**                                                                                                      

  F                                                                                             2.53    0.0114                                                                                     

  M                                                                                             0.017   7                  −2.178    0.0294               GCL~G~TT                                 

  All                                                                                           0.021   17                 −2.46     0.0138               GTS~A~TT                                 

  M                                                                                             8       −2.255             0.0241                                                                  

  M                                                                                             0.035   18                 1.964     0.0495               ACL~A~TA                                 

  **3' Block**\                                                                                 All     0.011              8         2.381                0.0172                                   G\[267\]G\[284\]AG
  **rs6355:Int2:rs140700:Int7:rs4583306:rs7224199**                                                                                                                                                

  F                                                                                             2.429   0.0151                                                                                     

  M                                                                                             0.015   8                  2.333     0.0196               G\[300\]A\[267\]AG                       

  0.029                                                                                         12      1.982              0.0474    G\[267\]G\[288\]AT                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Haplotype blocks shown graphically in [OS Figure 3](#SD4){ref-type="supplementary-material"}.

Best individual haplotype p-value, uncorrected.

Int2 alleles 9--12, and Int7 alleles 1--7, correspond to the following amplicon sizes \[bp\], respectively: 9=250, 10=267, and 12=300; and 1=263, 2=267, 3=271, 4=280, 5=284, 6=285, and 7=288.

LPR-rs25531 indicates functional phase-known haplotype at the LPR locus, e.g., L~A~, L~G~, S~A~ or S~G~.
